|
Age related macular degeneration
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
MACULAR DEGENERATION, AGE-RELATED, 8
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Age related macular degeneration
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
1093 patients with exudative AMD and 396 controls have been recruited and genotyped for the Y402H of CFH, rs10490924 of ARMS2 and T280M of the CX3CR1 gene.
|
21621535 |
2011 |
|
Age related macular degeneration
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Age-related macular degeneration (AMD), a complex multigenic disorder and the most common cause of vision loss in the elderly, is associated with polymorphisms in the LOC387715/ARMS2 and HTRA1 genes on 10q26.
|
18535016 |
2008 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD is a complex disorder caused by genetic and environmental factors in which single nucleotide polymorphisms (SNPs) in the genes CFH and LOC387715/HTRA1/ARMS2 have prognostic importance for progression to advanced AMD (with visual loss).
|
19015224 |
2009 |
|
Age related macular degeneration
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
19202148 |
2009 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
19202148 |
2009 |
|
Age related macular degeneration
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
20238042 |
2010 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers.
|
20238042 |
2010 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD patients with risk variants at rs1061170 (rs1061170" genes_norm="3075">CFH:p.Y402H) and ARMS2 and smokers (≥20 packs/year) were significantly earlier affected by AMD than those carrying the non-risk variants at each locus.
|
23103884 |
2013 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD-associated variants at the chromosome 10q26 locus and the stability of ARMS2 transcripts.
|
23942973 |
2013 |
|
Glycogen storage disease type II
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AMD (n=316) was strongly associated with CFH (p=1.78×10(-7)) and ARMS2 genotypes (p=1.67×10(-8)).
|
26614632 |
2016 |
|
Drusen
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Drusen area ≥ the median was independently associated with a higher number of risk alleles for CFH risk score and risk variants in C3 and ARMS2/HTRA1 compared with eyes with no measurable drusen.
|
31658355 |
2019 |
|
Age related macular degeneration
|
0.700 |
Biomarker
|
disease |
BEFREE |
ARMS2 was mainly distributed in the cytosol, not in the mitochondrial outer membrane as previously reported, suggesting that ARMS2 may not confer risk to AMD through the mitochondrial pathway.
|
19255159 |
2009 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy.
|
19268887 |
2009 |
|
Polypoidal choroidal vasculopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 (LOC387715) variants in Japanese patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy.
|
19268887 |
2009 |
|
Familial (FPAH)
|
0.010 |
Biomarker
|
disease |
BEFREE |
ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations.
|
19696174 |
2010 |
|
Age related macular degeneration
|
0.700 |
Biomarker
|
disease |
BEFREE |
ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations.
|
19696174 |
2010 |
|
Retinal angiomatous proliferation
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 A69S has a strong association with all three subtypes, with the association being strongest for RAP and weakest for PCV.
|
20574013 |
2010 |
|
Polypoidal choroidal vasculopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 A69S has a strong association with all three subtypes, with the association being strongest for RAP and weakest for PCV.
|
20574013 |
2010 |
|
Age related macular degeneration
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
ARMS2 and HTRA1 mRNA levels did not show a significant difference in expression among the control (young and elderly) and AMD retinas.
|
20664794 |
2010 |
|
Age related macular degeneration
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration.
|
21122828 |
2011 |
|
Polypoidal choroidal vasculopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 variants are likely associated with the phenotype and the effects of PDT in tAMD and PCV.
|
21541271 |
2011 |
|
Age related macular degeneration
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 rs10490924 was also significantly associated with the risk allele T found at a frequency of 0.5 in AMD and 0.15 in controls (p < 0.017, χ(2) test).
|
23362846 |
2013 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
|
28744656 |
2017 |